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Abstract 
Tachyarrhythmias are the most frequently observed cardiac complications during pregnancy. The majority 
of these maternal and foetal arrhythmias are supraventricular tachyarrhythmias; ventricular 
tachyarrhythmias are rare. The use of anti-arrhythmic drugs (AADs) during pregnancy is challenging due to 
potential foetal teratogenic effects. Maintaining stable and effective therapeutic maternal drug levels is 
difficult due to haemodynamic and metabolic alterations. Pharmacological treatment of tachyarrhythmias is 
indicated in case of maternal haemodynamic instability or hydrops fetalis. Evidence regarding the efficacy 
and safety of AAD therapy during pregnancy is scarce and the choice of AAD should be based on individual 
risk assessments for both mother and foetus. This review outlines the current knowledge on the 
development of tachyarrhythmias during pregnancy, the indications for and considerations of 
pharmacological treatment and its potential side-effects. 
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Cardiac arrhythmias during pregnancy pose a serious threat to the health of both mother and foetus. 
Women with established tachyarrhythmias, congenital heart defects or channelopathies have the highest 
risk for development of arrhythmias.
1,2
 They also develop de novo or occur in women without apparent heart 
diseases. Tachyarrhythmias, including both supraventricular and ventricular tachycardias, are the most 
common cardiac complications observed during pregnancy. Not only the mother, but also the foetus may 
develop tachyarrhythmias.
3
 The exact mechanisms underlying the development of cardiac arrhythmias 
during pregnancy are unknown, and selection of the appropriate treatment modality is hampered by the lack 
of randomised studies in pregnant women.
1,4,5
 This review outlines the current knowledge on the 
development of tachyarrhythmias during pregnancy, the indications for and considerations of 
pharmacological treatment and its potential side-effects. 
Incidences of Cardiac Arrhythmia During Pregnancy 
Maternal Arrhythmias 
(Supra)ventricular premature beats are the most frequently observed arrhythmias during pregnancy 
followed by paroxysmal supraventricular tachycardias (SVT); incidences are 33 and 24 per 100,000 
pregnancies respectively.
6
 Atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentry 
tachycardia (AVRT) are the most common supraventricular tachycardias both in pregnant and non-pregnant 
women with structurally normal hearts and usually do not cause haemodynamic deterioration.
7,8
 Studies 
investigating the risk of first onset paroxysmal SVT have shown inconsistent results.
7,9–12
 Tawam et 
al.
9
 described development of de novo paroxysmal SVTs during pregnancy in 13 out of 38 women (34 %). 
This is in contrast to a study by Lee et al.
7
 who reported development of de novo paroxysmal SVT in only 
3.9 % of the pregnancies. Recurrences were observed in 55 out of 65 (85 %) pregnant women with a 
history of paroxysmal SVT.
7
 In women with congenital heart disease (CHD) arrhythmias, mainly SVT, 
occurred in 4.5 % and were associated with multiple factors, including the presence of cyanotic heart 
disease (corrected/uncorrected) and usage of cardiac medication prior to gestation.
1,13
 Focal atrial 
tachycardia (FAT) occurs rarely during pregnancy and has mainly been described in case reports.
14–19
 Atrial 
fibrillation (AF) or atrial flutter (AFL) develop infrequently during pregnancy; a combined incidence of 2 per 
100,000 pregnancies has been reported.
6
 In patients with known AF/AFL, a recurrence rate of 52 % has 
been described.
20
 
The overall incidence of ventricular tachyarrhythmias (VT) or fibrillation (VF) in pregnant women is also very 
low (2 per 100,000 pregnancies).
6
 In women with structurally normal hearts monomorphic VT may develop 
during pregnancy, for example as a result of coronary artery disease or left ventricular dysfunction.
21,22
 VTs 
occur more often in patients with underlying acquired (coronary artery disease, valvular heart disease, 
peripartum cardiomyopathy) or inherited (CHD or channelopathies) heart disease. VT recurrences have 
been described in 27 % of women with heart disease and VT episodes prior to pregnancy.
20
 
Foetal Arrhythmias 
Foetal tachyarrhythmias occur in approximately 2 % of pregnancies. Most arrhythmias are paroxysmal SVT 
(73 %) or AFL (26 %).
23,24
 VTs have been described in a review by Krapp et al.
23
 in 3 out of 485 cases (0.6 
%) and may be associated with myocarditis, total atrioventricular block or congenital long QT syndrome.
25
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Haemodynamic Alterations During Pregnancy 
During pregnancy, the cardiovascular system is faced with significant changes which can precipitate the 
occurrence of arrhythmias. First, the blood volume increases by 35–40 % and is accompanied by an 
increase in heart rate and simultaneous decrease in vascular resistance. This leads to an increase in 
cardiac output of 30–50 %, already starting within the first weeks of pregnancy and with the largest increase 
occuring in the first 16 weeks.
26–30
 The increased blood volume has a physiological structural impact on the 
heart. The ventricles and atria dilate and the left ventricular mass increases during pregnancy.
27,31
 These 
effects are even greater in twin/multiple pregnancies.
27,32
 Mechanical stretch can facilitate arrhythmias by 
depolarisation of the membrane potential, premature depolarisations and dispersion in 
refractoriness.
33,34
 Furthermore, the increase in heart rate during pregnancy may act as a trigger in 
susceptible patients.
35
 There are also indications that oestrogen and progesterone may contribute to altered 
cardiac repolarisation facilitating arrhythmias.
36
 
Besides the hyperdynamic state and altered hormonal status possibly predisposing pregnant women to 
arrhythmias, the high incidence of arrhythmias in patients with pre-existent heart disease or previous 
arrhythmic episodes indicates that this is probably the most important risk factor for arrhythmias in 
pregnancy.
20
 
Indications and Considerations for Anti-arrhythmic Drug Therapy during Pregnancy 
The goal of anti-arrhythmic drug (AAD) therapy in general is to reduce ectopic activity or to modify critically 
impaired conduction. The ideal AAD has a greater effect on the arrhythmogenic substrate than on normal 
depolarising tissues, decreases mortality and has no sideeffects. However, many of the currently available 
AADs have proarrhythmogenic effects and could even increase mortality.
4
 
Pharmacological therapy of a pregnant woman is imperative in case of haemodynamic instability and/or 
diminished placentouterine blood flow. The main issue of pharmacological treatment of tachyarrhythmias 
during gestation is the potential teratogenic effect on the foetus as most AADs cross the placental barrier. 
Maintenance of adequate therapeutic drug levels in pregnant women is challenged by an increased 
intravascular volume, reduction of plasma proteins concentrations, increased renal blood flow and hepatic 
metabolism. Gastrointestinal absorption is also altered by changes in gastric secretion and intestinal 
motility.
37,38
 Foetal tachyarrhythmias should be treated when there is a risk of developing foetal heart failure. 
Subsequently, hydrops fetalis may develop and premature delivery or foetal death may occur.
39,40
 
Effects and Safety of Anti-arrhythmic Drugs 
There are very limited data available for the effects and safety of AAD therapy in pregnancy. The US Food 
and Drug Administration (FDA) has classified drugs into five categories (A–D and X) to indicate the 
supposed effects and level of evidence. In categories A and B studies did not show any foetal toxic effects, 
where in category B the evidence is only from animal studies. In category C there have been adverse foetal 
effects demonstrated in animal studies, and in category D adverse foetal effects have been reported in 
human studies. However, for all these categories potential benefits may outweigh the risks and the drug 
may therefore be administrated if the situation requires it. Only in category X is the drug clearly 
contraindicated due to substantial evidence for adverse foetal effects. Here the risks do not outweigh the 
possible benefits. However, it is important to keep in mind that this system is a simplified classification and 
detailed drug information should be used when determining the potential safety in individual patients. Table 
1 demonstrates that for most AADs some negative foetal effects have been reported in animal studies 
(category C), the most safe AADs appear to be lidocaine and sotalol and most adverse foetal effects during 
pregnancy have been reported with amiodarone and atenolol. The negative foetal effects of AADs that have 
been reported are also summarised in Table 1.4,
41–44
 The American Academy of Pediatrics (AAP) has 
classified most AADs as compatible with breastfeeding; only atenolol and amiodarone are possibly less 
favourable to use during the lactation period.
45
 AADs during pregnancy have been more extensively 
investigated for the treatment of foetal arrhythmias. The AADs recommended for foetal arrhythmias include 
sotalol and digoxin.
46
 
Drug Therapy 
Supraventricular Tachycardia 
If immediate conversion of AVNRT or AVRT is required and the vagal manoeuvre is unsuccessful, 
administration of adenosine IV is recommended.
3,4
 This terminates approximately 90 % of the AV(N) 
RTs;
47
 an alternative is IV metoprolol.
3
 If long-term treatment for AVNRT is required, digitalis or metoprolol 
are the first-line drugs.
3
 Electrical or pharmacological cardioversion for FAT, although often successful, is 
discouraged due to the relatively high risk of recurrences and is only indicated in case of haemodynamic 
instability. Administration of adenosine may successfully terminate FAT in 30 %.
4
 Rate control in FAT is 
indicated for the prevention of tachycardiomyopathy and can be achieved with the use of digitalis or 
metoprolol.
3,4
 Flecainide or propafenone could be considered for rhythm control therapy. Use of the lowest 
effective dose of amiodarone should only be considered when the FAT results in haemodynamic instability, 
it is refractory to all other AADs and conversion to sinus rhythm is required.
4
 
In case of AF or AFL requiring conversion to sinus rhythm, the use of ibutilide or flecainide is effective and 
recommended for non-pregnant patients,
48,49
 however experience of these drugs during pregnancy is 
limited.
3,4
 In pregnant women with an AF or AFL episode with a duration longer than 48 hours that requires 
direct current cardioversion, the use of oral anticoagulants at least three weeks before cardioversion is 
necessary.
4
 Atrial stunning after cardioversion increases the risk of thromboembolic events, and it is 
therefore recommended that oral anticoagulants are continued for at least four weeks.
4
 Oral anticoagulants 
should be replaced by low molecular weight heparin in the first and third trimester of pregnancy because of 
the potential negative effects on the foetus. Metoprolol is the drug of first choice to control ventricular heart 
rate. Verapamil is the drug of second choice since the blood levels of digoxin during pregnancy are 
unreliable. Propafenone or flecainide in conjunction with AV nodal blocking agents or sotalol can be used 
when other rate control strategies fail.
3,4,48,49
 
Ventricular Tachycardia 
Acute treatment of ventricular tachycardia (VT) is indicated in all patients and can be achieved by electrical 
(first choice) or pharmacological cardioversion.4 Amiodarone IV should only be used if VT persists, or when 
the VT is refractory to electrical cardioversion, drug resistant and haemodynamically comprising. Patients 
with structurally normal hearts or congenital long QT syndrome should be treated with b-blockers as a 
prophylaxis for development of VT recurrences. Verapamil could also be considered in patients without 
structural heart disease.
3,4
 
Foetal Arrhythmias 
As mentioned above, persistence of foetal arrhythmias predisposes for development of hydrops fetalis, 
ventricular dysfunction or eventually death.
4
 Hence, treatment of persistent foetal arrhythmias is indicated. 
Pharmacological treatment of primary foetal arrhythmias includes digoxin as the first choice.
46
 If 
unsuccessful, sotalol and verapamil, procainamide or quinidine can be administered. Sodium and 
potassium channel blockers have been safely applied during foetal ventricular arrhythmias.
50,51
 If maternal, 
transplacental treatment is not successful, umbilical or intraperitoneal
52
 drug administration or direct foetal 
intramuscular injection
53
 of anti-arrhythmic agents have been described. However, this approach has not 
(yet) been incorporated in the European or American Guidelines. 
Conclusion 
Prescription of anti-arrhythmic drug therapy in pregnant women is challenging due to the potential severe 
side-effects in both the mother and foetus. In addition, there are no major studies guiding selection of the 
safest and most effective anti-arrhythmic drug. Hence, initiation of anti-arrhythmic drug therapy requires 
careful consideration of the potential risks and benefits to the individual patient. 
Clinical Perspective 
 Initiation of anti-arrhythmic drug therapy requires careful consideration of the potential risks and 
benefits to the individual patient. 
 Pharmacological therapy of a pregnant woman is required in cases of haemodynamic instability 
and/or diminished placento-uterine blood flow. 
 However, the use of AADs during pregnancy should be avoided whenever possible. 
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